Blocking EPO Signaling Eliminates Immune-Resistant Liver Tumors in Mice

New research reveals tumor-derived erythropoietin suppresses immune responses, with combined EPO blockade and anti-PD-1 therapy achieving complete tumor regression in preclinical models.